InsiderTrades.com logo
Paul K. Audhya net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Paul Audhya Biography and Net Worth

Insider of KalVista Pharmaceuticals

Paul joined as Chief Medical Officer in May 2021. Dr. Audhya has over 20 years of clinical development and global medical affairs leadership experience across a range of therapeutic areas and disciplines, including rare disease. Most recently, he was Senior Vice President, Global Medical Affairs at Arena Pharmaceuticals, Inc., where he established and provided oversight for all medical affairs functions including Health Economics and Outcomes Research and Global Patient Advocacy. Prior to that, he was Vice President, Global Strategy and Phase 4, Global Medical Affairs at Vertex Pharmaceuticals, Inc., where he led global launch and lifecycle management planning and implementation for the cystic fibrosis portfolio. Before Vertex, Dr. Audhya was Vice President, Medical Affairs at Hospira Inc. (acquired by Pfizer) where he introduced transformational strategies for biosimilars globally and led the successful launch of the first monoclonal biosimilar in the EU. In the years prior to Hospira, Dr. Audhya held positions of increasing responsibility across all stages of drug development at Reata Pharmaceuticals, Abbott Laboratories, Amgen, Bristol Myers Squibb and Janssen. Dr. Audhya received a BA and MD from New York University, an MBA from Pepperdine University, and completed his residency in Internal Medicine at the University of Medicine and Dentistry of New Jersey.

What is Paul K. Audhya's net worth?

The estimated net worth of Paul K. Audhya is at least $1.34 million as of May 23rd, 2025. Dr. Audhya owns 113,026 shares of KalVista Pharmaceuticals stock worth more than $1,343,879 as of May 29th. This net worth evaluation does not reflect any other assets that Dr. Audhya may own. Additionally, Dr. Audhya receives a salary of $736,820.00 as Insider at KalVista Pharmaceuticals. Learn More about Paul K. Audhya's net worth.

How old is Paul K. Audhya?

Dr. Audhya is currently 51 years old. There are 6 older executives and no younger executives at KalVista Pharmaceuticals. The oldest executive at KalVista Pharmaceuticals is Dr. Christopher M. Yea Ph.D., Chief Development Officer, who is 60 years old. Learn More on Paul K. Audhya's age.

What is Paul K. Audhya's salary?

As the Insider of KalVista Pharmaceuticals, Inc., Dr. Audhya earns $736,820.00 per year. The highest earning executive at KalVista Pharmaceuticals is Mr. Benjamin L. Palleiko, CEO & Director, who commands a salary of $983,070.00 per year. Learn More on Paul K. Audhya's salary.

How do I contact Paul K. Audhya?

The corporate mailing address for Dr. Audhya and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at ir@kalvista.com. Learn More on Paul K. Audhya's contact information.

Has Paul K. Audhya been buying or selling shares of KalVista Pharmaceuticals?

Within the last three months, Paul K. Audhya has sold $57,139.10 in KalVista Pharmaceuticals stock. Most recently, Paul K. Audhya sold 2,146 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $11.31, for a transaction totalling $24,271.26. Following the completion of the sale, the insider now directly owns 113,026 shares of the company's stock, valued at $1,278,324.06. Learn More on Paul K. Audhya's trading history.

Who are KalVista Pharmaceuticals' active insiders?

KalVista Pharmaceuticals' insider roster includes Paul Audhya (Insider), Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Benjamin Palleiko (Chief Executive Officer and Director), Michael Smith (VP), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.

Are insiders buying or selling shares of KalVista Pharmaceuticals?

During the last year, KalVista Pharmaceuticals insiders bought shares 6 times. They purchased a total of 261,055 shares worth more than $2,397,646.35. During the last year, insiders at the specialty pharmaceutical company sold shares 16 times. They sold a total of 96,582 shares worth more than $1,049,119.87. The most recent insider tranaction occured on May, 23rd when insider Paul K Audhya sold 2,146 shares worth more than $24,271.26. Insiders at KalVista Pharmaceuticals own 10.5% of the company. Learn More about insider trades at KalVista Pharmaceuticals.

Information on this page was last updated on 5/23/2025.

Paul K. Audhya Insider Trading History at KalVista Pharmaceuticals

See Full Table

Paul K. Audhya Buying and Selling Activity at KalVista Pharmaceuticals

This chart shows Paul K Audhya's buying and selling at KalVista Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$57ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $11.89
Low: $11.31
High: $11.93

50 Day Range

MA: $11.91
Low: $10.32
High: $13.77

2 Week Range

Now: $11.89
Low: $7.30
High: $15.50

Volume

445,968 shs

Average Volume

422,405 shs

Market Capitalization

$591.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05